🏛️ Verified NIH Record • Updated 2026-03-25
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT06132256)
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Syndax Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
Who can join: Review the eligibility criteria below.
Location: Royal Prince Alfred Hospital — Camperdown, New South Wales
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (78 Sites)
Showing the first 25 of 78 sites.
- Royal Prince Alfred Hospital — Camperdown, New South Wales
- Sunshine Coast University Hospital — Birtinya, Queensland
- Wallace Street Specialist Centre — Brisbane, Queensland
- Mater Misericordiae Ltd — South Brisbane, Queensland
- Griffith University Clinical Trial Unit — Southport, Queensland
- Mackay Hospital & Health Service — West Mackay, Queensland
- Monash Health — Clayton, Victoria
- Institute for Respiratory Health — Perth, Western Australia
- OLV Hospital Aalst — Aalst, Oost-Vlaanderen
- AZ Groeninge — Kortrijk, West-Vlaanderen
- Centre de Recherche Clinique - CHUS — Sherbrooke, Quebec
- Dynamic Drug Advancement — Ajax,
- Thomayer University Hospital — Prague,
- CHU Amiens — Amiens,
- Chu Brest — Brest,
- CHU Dijon — Dijon,
- CHU de Rennes — Rennes,
- Klinikum Konstanz, Innere Medizin, Pneumologie — Konstanz, Baden-Wurttemberg
- Pneumologisches Studienzentrum München-West — Munich, Bavaria
- Medizinische Hochschule Hannover — Hanover, Lower Saxony
- Klinikum Chemnitz - Zentrum für klinische Studien — Chemnitz,
- Studienzentrum Dr. Keller — Frankfurt am Main,
- Asklepios Lungenklinik Gauting — Gauting,
- RoMed Klinikum Rosenheim — Rosenheim,
- Ospedale Colonnello D'Avanzo — Foggia, Apulia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.